Table 3.

Association between different early molecular parameters and OS, TFS, FFS, EFS, and optimal response (OR)

BCR–ABLIS transcript thresholdPatients at risk (%)Relative riskP
Overall survival
Ref. gene GUS
Diagnosis: 18.55%
 <18.55% (low risk)162 (67.5)1.140.132
 >18.55% (high risk)78 (32.5)
Ref. gene ABL
3 months: 10%
 <10% (low risk)161 (78.5)1.610.132
 >10% (high risk)44 (21.5)
Ref. Gene ABL
6 months: 1%
 <1% (low risk)149 (69.6)2.70.025
 >1% (high risk)65 (30.4)
Transformation-free survival
Ref. gene GUS
Diagnosis: 18.79%
 <18.79% (low risk)165 (68.8)2.030.029
 >18.79% (high risk)75 (31.2)
Ref. gene ABL
3 months: 10%
 <10% (low risk)161 (78.5)1.990.134
 >10% (high risk)44 (21.5)
Ref. gene ABL
6 months: 1%
 <1% (low risk)149 (69.6)2.20.021
 >1% (high risk)65 (30.4)
Failure-free survival
Ref. gene GUS
Diagnosis: 14.89%
 <14.89% (low risk)135 (56.2)3.82<0.001
 >14.89% (high risk)105 (43.8)
Ref. gene ABL
3 months: 10%
 <10% (low risk)161 (78.5)2.89<0.001
 >10% (high risk)44 (21.5)
Ref. gene ABL
6 months: 1%
 <1% (low risk)149 (69.6)7.48<0.001
 >1% (high risk)65 (30.4)
Event-free survival and optimal response
Ref. gene GUS
Diagnosis: 15.94%
 <15.94% (low risk)142 (59.2)1.97<0.001
 >15.94% (high risk)98 (40.8)
Ref. Gene ABL
3 months: 10%
 <10% (low risk)160 (78.5)1.99<0.001
 >10% (high risk)44 (21.6)
Ref. gene ABL
6 months: 1%
 <1% (low risk)149 (69.6)2.75<0.001
 >1% (high risk)65 (30.4)